Rigel Pharmaceuticals Revenue and Competitors

San Francisco, CA Indonesia

Location

$192.5M

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • Rigel Pharmaceuticals's estimated annual revenue is currently $147.3M per year.(i)
  • Rigel Pharmaceuticals received $71.8M in venture funding in April 2018.
  • Rigel Pharmaceuticals's estimated revenue per employee is $564,291
  • Rigel Pharmaceuticals's total funding is $192.5M.
  • Rigel Pharmaceuticals's current valuation is $413.8M. (January 2022)

Employee Data

  • Rigel Pharmaceuticals has 261 Employees.(i)
  • Rigel Pharmaceuticals grew their employee count by -2% last year.

Rigel Pharmaceuticals's People

NameTitleEmail/Phone
1
COOReveal Email/Phone
2
CFOReveal Email/Phone
3
VPReveal Email/Phone
4
EVP, General Counsel and Corporate SecretaryReveal Email/Phone
5
EVP, Corporate Affairs and General CounselReveal Email/Phone
6
VP Market Access & Patient ServicesReveal Email/Phone
7
VP, Marketing and Commercial StrategyReveal Email/Phone
8
SVP Human ResourcesReveal Email/Phone
9
EVP & Head Research at Rigel Pharmaceuticals Inc.Reveal Email/Phone
10
SVP, Corporate DevelopmentReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$4.4M57-8%$53MN/A
#2
$21.2M137-26%$110MN/A
#3
$0.9M60%N/AN/A
#4
$2.3M1515%N/AN/A
#5
$1.6M10-17%N/AN/A
#6
$0.7M950%N/AN/A
#7
$11.5M74-12%N/AN/A
#8
$0.4M27510%$236.7MN/A
#9
$4M51-74%$160MN/A
#10
$2.3M1515%N/AN/A
Add Company

What Is Rigel Pharmaceuticals?

Rigel Pharmaceuticals, Inc., is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases.

keywords:Biotechnology,Cleantech,Healthcare,Pharmaceuticals,Wind Power

$192.5M

Total Funding

261

Number of Employees

$147.3M

Revenue (est)

-2%

Employee Growth %

$413.8M

Valuation

N/A

Accelerator

Rigel Pharmaceuticals News

2022-04-19 - Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Short Interest ...

Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Short Interest Down 22.3% in March. Posted by admin on Apr 18th, 2022. Share on Twitter Share on Facebook Share on...

2022-04-17 - Rigel Pharmaceuticals, Inc. (RIGL) Stock Falls -0.96% This Week: Is It a Good Pick?

Rigel Pharmaceuticals, Inc. (RIGL) stock is down -13.85% over the last 12 months, and the average rating from Wall Street analysts is a...

2022-03-22 - Rigel Pharmaceuticals: Why The Stock Is On A Run

In early March, Rigel Pharmaceuticals Inc. (NASDAQ:RIGL) reported a near miss on revenues for Q4'21, but the stock rallied nonetheless and...

2021-11-02 - Rigel Reports Third Quarter 2021 Financial Results and Provides Business Update - Form 8-K

Rigel Reports Third Quarter 2021 Financial Results and Provides Business Update - Completed enrollment of FORWARD Phase 3 trial of fostamatinib in patients with warm autoimmune hemolytic anemia (wAIHA), topline data expected mid-2022 - Rigel's Phase 3 trial in high-risk hospitalized patients ...

2021-11-02 - Rigel Reports Third Quarter 2021 Financial Results and Provides Business Update

SOUTH SAN FRANCISCO, Calif., Nov. 2, 2021 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today reported financial results for the third quarter ended September 30, 2021, including sales of TAVALISSE® (fostamatinib disodium hexahydrate) tablets for the treatment of adults with chronic ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$95.1M2625%N/A
#2
$197.9M266-11%$194.5M
#3
$29.7M2707%N/A
#4
$10.1M300-13%N/A
#5
$69M31819%$743M

Rigel Pharmaceuticals Funding

DateAmountRoundLead InvestorsReference
2002-01-18$31.5MPublic OfferingArticle
2003-05-01$46.0MLead Investor: MPM CArticle
2003-06-30$46.0MCommon StockMPM CapitalArticle
2003-08-04$9.3MRights OfferingArticle
2009-09-19$108.3MUndisclosedCredit Suisse Securities (USA)Article
2011-05-26$UndisclosedUndisclosedJefferies & Company Inc, J P Morgan Securities LLCArticle
2012-10-04$130.0MUndisclosedJefferies & Company Inc, J P Morgan Securities LLCArticle
2017-02-01$40.0MUndisclosedJefferies LLCArticle
2017-10-04$46.0MUndisclosedJefferies LLCArticle
2017-10-05$69.7MUndisclosedBMO Capital Markets CorpArticle
2018-04-20$71.8MUndisclosedJefferies LLCArticle